Modesto Orozco’s lab (IRB Barcelona) has published a study on the reaction mechanism of DNAzymes in Nature Catalysis.
DNAzymes, which are catalysers formed by DNA, have applications in biomedicine and biotechnology. These research results will contribute to advances in the design and improvement of catalysers for therapeutic purposes.
Modesto Orozco’s laboratory (IRB Barcelona) has published a study on the source of asymmetry between nucleic acid hybrid (RNA and DNA) in CHEM (Cell Press).
The results are a promising step towards enhancing gene therapies, which are applicable to many diseases.
Kennedy’s disease is an untreatable neuromuscular disorder considered a rare disease
A study led by Xavier Salvatella may pave the way for new lines of treatment for Kennedy’s disease
A study done by scientists at IRB Barcelona can simulate and predict the shape of a molecule in function of its environment.
These results mark a milestone for the computational design of molecules with specific shape and features for agrochemical, technological and pharmaceutical applications.
The research group led by Travis Stracker identifies genes involved in male infertility in mice.
Their findings are relevant in humans and could explain undiagnosed cases of male infertility or subfertility.
In mice whose body clock—an internal mechanism located in the brain—does not work properly, each tissue still knows what time it is and has the capacity to respond to changes in light intensity.
The study, published in the journal Cell, is a collaboration between IRB Barcelona and the University of California, Irvine (US).
This research will help to identify those genes that play a key role in the initiation of metastasis
Metastasis causes 90% of cancer related deaths
Work headed by scientist Antonio Zorzano proposes a possible therapeutic target to treat fatty liver, a disease for which there is currently no treatment.
The study, which was done in collaboration with the Pere Virgili Institute, has been published in the journal Cell.
The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now.
The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies.
Mutations in L-amino acid transporters (LATs) can lead to a wide range of conditions, such as autism, hearing loss and aminoacidurias.
Published in the journal Nature Communications, this study presents key data on how amino acids bind to these transporters.
The work is a collaboration between IRB Barcelona, CIBERER, IBMB-CSIC and the Barcelona Supercomputing Center.
